Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyLeukemiaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
A MyLeukemiaTeam Member asked a question 💭
Quang ngai, VietNam
February 6
 · 
Reactions
A MyLeukemiaTeam Member

If the MRD is 0.07%, what is the next course of treatment?

February 6
MyLeukemiaTeam

What is the recurrence-free survival rate with an MRD of 0.07% after the maintenance phase?

Unfortunately, the available information doesn't provide specific recurrence-free survival rates for an MRD level of 0.07% after maintenance therapy.

What we do know is that MRD testing helps predict outcomes:

- Negative MRD Show Full Answer

What is the recurrence-free survival rate with an MRD of 0.07% after the maintenance phase?

Unfortunately, the available information doesn't provide specific recurrence-free survival rates for an MRD level of 0.07% after maintenance therapy.

What we do know is that MRD testing helps predict outcomes:

- Negative MRD results (no cancer cells detected) are associated with longer remissions and may indicate longer survival rates
- Positive MRD results (cancer cells detected) suggest a higher risk of relapse
- MRD monitoring allows doctors to detect potential relapses earlier and adjust treatment accordingly

An MRD of 0.07% would be considered positive, meaning some leukemia cells remain detectable. However, the specific impact on your recurrence-free survival depends on several factors including:

- Your type of leukemia (ALL, AML, CLL, or CML)
- Your age and overall health
- Previous treatments received
- The specific subtype of your leukemia

Your doctor can provide more personalized information about what your specific MRD level means for your prognosis and whether any treatment adjustments might be beneficial. They have access to more detailed data and can consider your complete medical history when discussing your outlook.

February 6

Related Questions

View All
A MyLeukemiaTeam Member asked a question 💭
Quang ngai, VietNam

A MyLeukemiaTeam Member asked a question 💭
Apache Junction, AZ

A MyLeukemiaTeam Member asked a question 💭
Mississippi State, MS